Sepsis Diagnostics Market Outlook:
Sepsis Diagnostics Market size was valued at USD 997.07 million in 2026 and is expected to cross USD 2,275.22 million by the end of 2036, expanding at more than 8.6% CAGR during the forecast period, i.e., 2027-2036. In 2027, the industry size of sepsis diagnostics is assessed at USD 1,082.82 million.
The growth of the market can be attributed to the increasing number of elderly people who are prone to sepsis. Further, the growing technological advancements in the field of sepsis diagnostics are expected to add to the market growth. The United States Food and Drug Administration, FDA, granted marketing authorization to Immunoexpress Inc.'s SeptiCyte RAPID in December 2021. In October 2021, Prenosis Inc. extended an existing agreement with Roche Diagnostics to accelerate the clinical diagnosis of sepsis. Prenosis, Inc. is a precision diagnostic company that uses AI in order to help diagnose patients more accurately.
In addition to these, factors that are believed to fuel the growth of sepsis diagnostics market include the increase in sepsis cases, the increased burden of hospital-acquired infections, the rising number of pneumonia cases, a higher level of sepsis treatment, and an increase in funding for research related to sepsis. Increased use of sepsis diagnostic products is expected to contribute to market growth. In addition, a new intervention to actively prevent, treat and evaluate sepsis in pregnant women was funded by more than GBP 3 million in June 2021.
